Acobiom

Acobiom is a private, innovative biotech firm at the forefront of precision medicine diagnostics. Its core asset is GemciTest®, a blood-based diagnostic test designed to predict pancreatic cancer patient response to gemcitabine chemotherapy, aiming to optimize treatment selection. Beyond this lead program, the company operates a robust omics services business, providing RNA-Seq, qPCR, and bioinformatics analysis to support translational research for external clients. Acobiom's strategy combines service revenue with the high-value development of proprietary diagnostic tests.

Integrated genomics and bioinformatics platform for biomarker discovery. Includes proprietary bioinformatic tools, a 21,000 Human RNA-Seq database, and expertise in NGS (RNA-Seq) and PCR technologies (qPCR, digital PCR) for analyzing DNA, RNA, and miRNA.

Acobiom competes in the crowded biomarker and companion diagnostics space, facing large, established diagnostic companies (e.g., Roche, Qiagen, Myriad) and numerous small biotechs. In pancreatic cancer, competition includes other prognostic/predictive biomarkers (e.g., CA19-9, molecular subtyping) and emerging liquid biopsy tests. Its differentiation lies in its specific blood-based RNA signature and integrated bioinformatics platform.